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Abstract
Background: Ever since the first atomic structure of an enzyme was solved, the discovery of the mechanism and
dynamics of reactions catalyzed by biomolecules has been the key goal for the understanding of the molecular
processes that drive life on earth. Despite a large number of successful methods for trapping reaction
intermediates, the direct observation of an ongoing reaction has been possible only in rare and exceptional cases.
Results: Here, we demonstrate a general method for capturing enzyme catalysis “in action” by mix-and-inject serial
crystallography (MISC). Specifically, we follow the catalytic reaction of the Mycobacterium tuberculosis β-lactamase
with the third-generation antibiotic ceftriaxone by time-resolved serial femtosecond crystallography. The results
reveal, in near atomic detail, antibiotic cleavage and inactivation from 30 ms to 2 s.
Conclusions: MISC is a versatile and generally applicable method to investigate reactions of biological
macromolecules, some of which are of immense biological significance and might be, in addition, important
targets for structure-based drug design. With megahertz X-ray pulse rates expected at the Linac Coherent Light
Source II and the European X-ray free-electron laser, multiple, finely spaced time delays can be collected rapidly,
allowing a comprehensive description of biomolecular reactions in terms of structure and kinetics from the same
set of X-ray data.
Background
Observing the catalytic action of a biomolecule in
atomic detail has been the dream of structural biologists
since the first structure of an enzyme was solved [1, 2].
By exploiting X-ray radiation from powerful synchrotron
sources, time-resolved crystallographic methods were
developed [3] with the goal of achieving a complete
description of a reaction in real time [4, 5]. However,
X-ray damage and the need for large single crystals
made time-resolved crystallography very challenging.
The advent of X-ray free-electron lasers (XFELs) has en-
abled time-resolved serial femtosecond (fs) crystallog-
raphy (SFX), where X-ray damage is outrun by
ultrashort fs X-ray pulses [6, 7]. This approach has made
it possible to follow and describe cyclic and non-cyclic
reactions triggered by light. Examples include pioneering
studies on the photoactive yellow protein [8, 9], myoglo-
bin [10], bacteriorhodopsin [11], photoswitchable fluor-
escent proteins [12, 13], and photosystem II [14–17].
However, structural investigations on one-pathway
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enzymatic reactions present additional difficulties, be-
cause diffusion of substrate(s) and products in and out
of the crystals limit the accessible reaction times. Stand-
ard crystallography can be used to track reaction inter-
mediates of slow reactions by flash cooling [18–20], but
the method is then unable to reveal enzymatic reactions
at room temperature in real time. The problem is to
start a reaction in large-sized crystals. Initiation by diffu-
sion is far slower in these crystals than the typical milli-
second turnover times of enzymes. It was proposed that
one can trigger enzymatic reactions by light by soaking
inactive (caged) substrates [21] into the crystals, which
then can be activated by a laser pulse. The first proof of
concept for time-resolved Laue crystallography triggered
by a caged substrate was achieved in 1990 [22]. While
this method has great potential, its application has so far
been limited due to significant experimental challenges.
Only a few time-resolved experiments have been re-
ported where highly reactive, caged substrates are readily
available [18, 22, 23], or the reactions are slow and allow
the use of more conventional methods [24, 25]. It is
therefore highly desirable to develop new methods that
open the field of time-resolved crystallography to the
study of biomolecular reactions at room temperature
with the native enzyme and its natural substrate(s).
Structural studies at XFELs offer the possibility of a
breakthrough. The XFEL intensity is high enough to
generate a diffraction pattern from an exposure to a sin-
gle fs X-ray pulse even from micrometer- and
submicrometer-sized crystals. These tiny crystals allow
for fast (sub-millisecond to millisecond) diffusion times,
which are not rate-limiting for many enzymatic reactions
[26–32]. The microcrystals are mixed “on the fly” and
injected into the XFEL beam, a method we call mix-an-
d-inject serial crystallography (MISC) [28, 30]. In MISC,
crystals react with their native substrate(s) at ambient
temperature until they are probed by a single X-ray
pulse that destroys them but not before a diffraction pat-
tern has been recorded. The pulses are short enough to
essentially outrun radiation damage by means of the
“diffraction-before-destruction” principle [33–35]. Opti-
mized injectors have been recently developed [36, 37]
for MISC experiments with the potential to provide sub-
millisecond time resolution [38]. The microcrystals may
tolerate even larger conformational changes leading to
unit cell or even space group changes [14, 31].
Here, we apply MISC to the study of a very important
public health problem: bacterial antibiotic resistance.
Specifically, we have obtained time-resolved crystallo-
graphic data on the binding and cleavage of the
third-generation antibiotic ceftriaxone (CEF) in micro-
crystals of the enzyme β-lactamase from Mycobacterium
tuberculosis (BlaC). Previous studies introduced muta-
tions into BlaC by exchanging catalytically important
residues to slow down (or stop) the reaction to the ex-
tent that the binding of numerous antibiotics to BlaC
could be studied [39]. In our experiments, however, car-
ried out at the Linac Coherent Light Source (LCLS), mi-
crocrystals of unmodified BlaC are mixed with CEF on
the fly, and the cleavage and thereby inactivation of the
antibiotics by the wild-type β-lactamase is followed at
runtime. BlaC is a broad-spectrum β-lactamase which
confers resistance to all classes of β-lactam antibiotics in
tuberculosis [19, 40]. BlaC chemistry has rendered the
frontline arsenal of antibacterial agents ineffective
against this deadly disease, creating a global public
health crisis.
Beginning with the famous discovery of penicillin,
β-lactam antibiotics were widely used to eliminate
deadly bacterial infectious diseases [41]. More com-
pounds with diverse chemical composition have been
found through the years [42], the most prominent of
them most likely the cephalosporins. The chemical
structure of CEF is shown in Fig. 1. Unlike the penicil-
lins, which feature a 5-membered thiazolidine ring, in
the cephalosporins a 6-membered dihydrothiazine ring
is fused to the β-lactam ring. However, rampant resist-
ance against these antibiotics was observed shortly after
their widespread use [41]. β-lactamases open the
β-lactam ring, thereby rendering the antibiotic inactive.
BlaC from M. tuberculosis, an Ambler class A
β-lactamase [43], uses a conserved serine to attack the
β-lactam ring (Fig. 1, blue arrow), thus inactivating the
antibiotics. Because of the medical challenge that BlaC
causes for the fight against infectious diseases, the
process of catalysis has been studied by conventional
biochemical methods in detail, leading to the hypothesis
of a three-step model of the cleavage process. The first
step is the formation of the enzyme-substrate (ES) com-
plex (Fig. 1, species 1), and it has been proposed that the
enzyme may use active site interactions to orient the
β-lactam carbonyl carbon near the Ser-70 nucleophile
[19, 40]. The next step proposed along the reaction co-
ordinate is the nucleophilic attack of Ser-70, which re-
sults in the opening of the β-lactam ring and the
formation of the covalently bound active site acyl inter-
mediate (species 3). For cephalosporins there is evidence
that during the enzymatic reaction a leaving group (de-
noted R in Fig. 1) is split off [44, 45]. In the third step,
the open-ring β-lactam ligand is hydrolyzed and released
by the enzyme (Fig. 1, species 4). Various rates have been
reported for this step of the catalytic reaction across dif-
ferent classes of β-lactams, followed by product release
[40]. Static structures of some of the critical intermedi-
ates have been determined and reported [19], including
an initial enzyme substrate complex trapped by removal
of catalytically important amino acid residues [39].
Obtaining time-resolved data on BlaC chemistry holds
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the potential to directly visualize substrate chemical in-
termediates and the accompanying active site interac-
tions, with wide-ranging implications for all classes of
β-lactams. Ultimately, knowledge of the molecular pro-
cesses by which BlaC is able to bind and catalyze the
breakdown of β-lactams will directly impact rational
drug design against deadly human diseases.
Our previous results at 2 s after mixing showed that
CEF can diffuse into the crystals and binds to the active
site of the crystalline β-lactamase [30]. These first stud-
ies showed that the catalytic reaction is heterogeneous,
as the reactivity is specific to individual copies of the
four β-lactamase chains in the asymmetric unit of the
crystal. Only subunits B and D bind and process CEF,
while subunits A and C do not directly contribute to ca-
talysis, at least on the time scale of our experiments
(Fig. 2a). This first proof-of-concept study was limited to
a single time point about 2 s after reaction initiation
[30]. Multiple time points covering the reaction are re-
quired for any kinetic analysis.
Results
Here we present a time series from 30 ms to 2 s after
mixing with substrate in two different crystal forms,
called shards and needles; this allows us to discover the
conformational changes and to characterize the kinetics
of this important class of enzymes directly from the
X-ray data. We base our interpretation on bias-free omit
maps obtained by simulated annealing. Figure 2 and
Additional file 1: Figures S2–S6 show details of these
maps near the active site. As a complement, more con-
ventional 2mFo-Fc maps are shown in Additional file 1:
Figures S7–S9.
The critical questions in MISC concern whether the
enzyme in the crystals is still catalytically active and
whether the reaction is limited by constraints of crystal
packing or the solvent/precipitant used for
crystallization. We have therefore crystallized BlaC in
two different crystal forms. With phosphate as the pre-
cipitant, the BlaC crystallizes in a shard-shaped crystal
form with four copies in the asymmetric unit (Fig. 2a) as
previously reported [30]. With polyethylene glycol (PEG)
1000 as the precipitant, needle-shaped crystals are ob-
tained with one molecule in the asymmetric unit. The
packing of BlaC in both crystal forms is shown in Add-
itional file 1: Figure S11.
In our MISC experiment, the small microcrystals were
rapidly mixed with CEF “on the fly” using optimized
mixing devices (Additional file 1: Figure S1), and struc-
tures of the reaction of BlaC with CEF were determined
by scattering from femtosecond X-ray pulses at five time
points (unmixed, and 30 ms, 100 ms, 500 ms, and 2 s
after mixing, respectively) during the reaction in both
crystal forms. Results are shown in Figs. 1 and 2. CEF
Fig. 1 Reaction of β-lactamase with ceftriaxone (CEF). (1) Formation of the enzyme substrate complex by non-covalently binding CEF. (2)
Nucleophilic attack of the active site residue Ser-70 results in rearrangement of double bonds and ultimately leads to the opening of the β-
lactam ring (blue arrow points to the bond to be cleaved) and the detachment of the leaving group (R). (3) Covalent bond formation between
Ser-70 and a shortened species (E-CFO*). Note the double bond Δ. The double bond may react with water to form an alcohol (OH). Evidence for
all four intermediate species is found in our experiments. (4) Species (3) is further hydrolyzed from Ser-70 and leaves the enzyme as product
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binds to the active site of BlaC as shown in Fig. 2a. In
Fig. 3 more details are shown for the substrate binding
in the shard and needle crystal forms (see also Add-
itional file 1: Figure S2 for details from another viewing
direction, and Additional file 1: Figures S3–S10 for ste-
reo representations of various viewing directions and
time points). Strong electron density at 30 ms shows
that substrate diffusion into the crystals was successful.
At this time delay the formation of the non-covalently
bound ES complex is observed (Fig. 3a, b, c). The ES
complex can be identified by strong electron density of
the leaving group sulfur (blue arrows in Fig. 3a, b), and
somewhat stronger dioxo-triazine ring features (red ar-
rows in Fig. 3a, b). Since the resolution of our X-ray data
at the 30-ms time delay is limited to 2.75 Å, the distinc-
tion between a non-covalently bound species and a cova-
lently bound species (see below) is difficult. However,
the non-covalently bound species dominates occupancy
refinements (see Table 2a, and remarks therein). At
100 ms the ES complex still prevails and is the major
component observed (~ 70%, see also Table 2). A minor
fraction (~ 30%) has an open β-lactam ring (Fig. 3d, e, f ).
The open, covalently bound species E-CFO* can be
identified more clearly at 500 ms, where it dominates
the electron density (Fig. 3g, h, i). Only on a time scale
longer than 100 ms does the nucleophilic attack of
Ser-70 open the β-lactam ring. At 500 ms this results in
high occupancy of an intermediate which is covalently
bound to the enzyme called E-CFO* as shown in Fig. 3g,
h, i. At the same time the leaving group R (Fig. 1) is split
off, as witnessed by the vanishing density of the leaving
group sulfur and some of the weak ring density features
(compare Fig. 3d and g, or Fig. 3e and h; see also feature
β in Additional file 1: Figure S10c). The covalently
bound ligand is much shorter than CEF. The red arrow
in Fig. 3g indicates that the double bond Δ (Fig. 1) may
have reacted to an alcohol in subunit B, which does not
occur in subunit D or in the needle form of the crystals.
Additional file 1: Figure S10 shows the density in the un-
mixed shard crystal form (Additional file 1: Figure S10a)
Fig. 2 Overview of BlaC as determined using 10 × 10 × 3 μm3 sized crystals in the shard form at 500 ms after mixing with 300 mM CEF at room
temperature. The mFo-DFc SA-omit electron density is shown for the covalently bound intermediate E-CFO* in green (contour level 2.5 σ).
Electron density of an additional, stacked ceftriaxone molecule near the active site is shown in dark green (contour level 2 σ). a The BlaC subunits
A–D displayed in blue, yellow, green and light yellow, respectively. Amino acid residues that interact with the stacked CEF are labeled. Panels b and
c show enlarged views of the active sites of subunits B and D, respectively. Arg-126 and Tyr-127 with which the respective stacked CEF molecules
interact are shown. Some important distances are also displayed (stacked molecules are also observed at the other time delays in the shard
crystal form but not in the needles)
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and a difference map between the 500 ms and the
100 ms time points (Additional file 1: Figure S10c),
which displays changes in the region of the covalent at-
tachment of the intermediate between 100 ms and
500 ms. At 2 s, the binding sites are occupied mainly by
the full-length CEF with a minor contribution from
E-CFO* (Table 2a, b).
In the multi-copy shard crystal form, subunits A and
C do not directly participate in catalysis, at least not in
the first 2 s. In the monomeric needle crystal form, it ap-
pears that the reaction proceeds similarly to that ob-
served in subunit D in the shards. However, substrate
occupancy is lower than that in the shards, with
substoichiometric occupancy ranging from 20% to 40%.
The reason for this might be that the enzyme is more
tightly packed in the needle crystal form (Additional file 1:
Figure S11). To reach full occupancy in the needles, at
least 30 mmol/L of CEF (one CEF molecule per asym-
metric unit) is initially required, which needs to be deliv-
ered by diffusion from the solution to the side of the
crystal. While the outside CEF concentration is on the
order of 200 mmol/L in both experiments (Table 3c),
the ratio of CEF to enzyme varies in the shard and nee-
dle crystals. Additional file 1: Figure S11 shows how the
solvent volume that contains CEF surrounding the BlaC
molecules in the crystals varies. The solvent volume as
Fig. 3 Ceftriaxone density in the active site in 10 × 10 × 3 μm3 shard and 5 × 2 × 2 μm3 needle crystal forms at various times after mixing with
200–300 mmol/L CEF. The main species is displayed in blue, the minor species in gray. First two columns: shard crystal form, mFo-DFc SA-omit
density (green) contoured at 2.5 σ. Third column: needle crystal form. SA omit maps were calculated using extrapolated structure factors. Time
delays are arranged from top (30 ms) to bottom (2 s). Black arrows show the electron density of the covalently bound acyl adduct (see also
Additional file 1: Figure S2 for details). a, b, c The ES complex at 30 ms. The full-length CEF model (blue) is displayed. The ES complex can be
observed in needles or shards (both subunits). Blue arrows: features of the leaving group sulfur, red arrows: dioxo-triaxine ring feature. d, e, f Early
phases of the formation of a covalently bound CEF adduct at 100 ms. The full-length CEF model (blue) is displayed together with the minor E-
CFO* species (gray), where the β-lactam ring is open and attached to Ser-70 in subunit-B (shard crystal form, panel d) and the needle crystal form
(panel f). In the shard crystal form subunit D (panel e) the acyl adduct is not yet observed. g, h, i Covalently bound adduct (E-CFO* in blue)
formation at 500 ms with a small contamination of full-length CEF (gray). The red arrow points to electron density that may favor the
interpretation by an OH group. j, k, l Mixture of the non-covalently bound, full-length CEF (blue arrow shows the leaving group sulfur feature)
and covalently bound E-CFO* in the shard crystal form (both subunits) at 2 s. The electron density in the needle crystal form favors only the full-
length CEF species
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estimated by the CCP4 program “truncate” [46] is on the
order of 59% for the shard-shaped crystal, and it is sub-
stantially lower (28%) in the needles. Additional file 1:
Figure S11 also shows that there are substantial differ-
ences in the solvent channel sizes in the two crystal
forms. When measured by the program Coot [47], cav-
ities with diameters as wide as 90 Å can be identified in
the shards, and only 20-Å voids exist in the needles.
Both may significantly impact diffusion of the CEF sub-
strate (which is about 20 Å long and 10 Å wide) into the
crystals. However, compared to other antibiotics such as
ampicillin [40], CEF binds relatively slowly to BlaC, so it
may first build up by diffusion (see also the discussion
below and estimates in the Methods section). Strong
electron density in our maps shows that diffusion and
formation of the ES complex is near completion on a
30-ms time scale. Diffusion times and time scales of the
ES formation (30 ms) are irrelevant compared to those
for the E-CFO* intermediate formation (~ 500 ms). As a
consequence, the ability to observe the E-CFO* inter-
mediate does not critically depend on CEF diffusion
times into the crystals (compare the solid and dashed
lines in Fig. 4). Accordingly, the reaction dynamics of
the catalytic reaction in the needle and the shard crystal
forms appear to be similar despite the different crystal
morphologies and packing (see further explanation in
the Methods section). Subtle differences between the re-
sults from the two crystal forms, and between the sub-
units in different crystal environments, confirm previous
preliminary results [30] and previous predictions from
biochemical results for other cephalosporin species [44].
An additional CEF molecule (CEFstack) can be identi-
fied near the catalytic clefts of subunits B and D, each in
the shard crystal form (Fig. 2a, b, c, and Additional file 1:
Figure S9). This molecule stacks to the CEF species that
occupy the active sites on all time scales. CEFstack is
non-covalently interacting with Arg-126 and Tyr-127 of
subunit A or C, which are adjacent to the active catalytic
clefts of subunit B or D, respectively. For more details
see Additional file 1: Figure S9 for a stereo view. This
way CEFstack is quite close, pre-oriented, and can rapidly
access the active site after the initial CFO has been hy-
drolyzed and has left the enzyme. Stacking of multiple
cephalosporin (cefamandole) molecules has also been
observed in orthorhombic crystals of the BlaC K73A
mutant [39]. In these crystals the stacked molecules
interact with Asp-192 and Arg-194 of a symmetrically
equivalent BlaC molecule; this is different from the in-
teractions seen here. As with most proteins, BlaC can
crystallize in crystal forms with different numbers of
copies in the asymmetric unit [39, 48, 49]. Since stacking
is not observed in crystals that pack in the same way as
our needle crystal form [19], it might be argued that it
represents a non-physiological, non-specifically bound
substrate that occurs only in the environment in the
shard crystals. However, the binding of the additional
CEF molecule could be a mechanism to steer the sub-
strate towards, and orient it with respect to, the active
site under certain conditions. It appears, however, that at
the very high concentrations of CEF applied here
(around 200 mmol/L), stacking is not required for effect-
ive catalysis, as the kinetics in the monomeric needles,
where stacking does not occur, is similar to that in the
shard crystal form. When only low CEF concentrations
are present, stacking might well be essential to recruit
antibiotic substrate molecules to promote effective BlaC
function.
Discussion
One of the major questions addressed here is whether
the structural data obtained by MISC can be interpreted
in accordance with previous investigations on BlaC ca-
talysis. Ideally, a compatible chemical kinetic mechanism
can be developed and expressed in the terminology of
enzyme kinetics [50, 51]. Accordingly, we set up a kin-
etic mechanism (see Methods, Scheme 1) which allows
for diffusion of substrate and which features a suffi-
ciently large number of intermediate states to explain
our observations. Initially, we simulated the catalytic
cycle employing literature values of the Michaelis con-
stant Km (~ 500 μmol/L) and kcat (0.8 s
− 1) [40] (Table 3).
Our simulations describe the change from the transient
state kinetics regime at 30 ms to 2 s, covering a large
Fig. 4 Concentration profile of the catalytic BlaC reaction with CEF
as simulated with realistic parameters and a kinetic mechanism as
discussed. The solid lines are calculated with τD = 15 ms, the dashed
lines with τD = 1.5 ms. Black lines: free enzyme (E). Green lines:
enzyme substrate complex (ES). Blue lines: enzyme acyl intermediate
complex (E-CFO*). Red lines: product P (CFO, inactive CEF without
leaving group, lactam ring open), released from the enzyme. Black
dots: time delays are shown together with the approximate
expected ratio of CEF to E-CFO*
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range of substrate and product concentrations. We then
vary the rate coefficients in the mechanism to explain
our MISC experiment. Since only five time delays are
available, the parameters in the mechanism cannot be
independently determined, but we do show that our in-
terpretation is consistent with known kinetic parameters
in solution. After initial formation of the ES complex
represented by a non-covalently bound full-length CEF,
the intermediate E-CFO* has its peak concentration at
500 ms. It has been previously suggested [19] that the
hydrolytic cleavage of an acyl adduct from Ser-70 (hy-
drolysis of species 3 in Fig. 1) should be the rate-limiting
step in BlaC catalysis. Then the E-CFO* species should
be the dominant species in the steady state. However,
this is not the case, as the ES complex with the
non-covalently bound, full-length CEF is prevalent (>
70%) in our MISC data at 2 s (Table 2). The simulation
can explain this, if the nucleophilic attack of Ser-70 on
species 2 in Fig. 1 is inhibited or slowed down. High
product concentrations of > 10 mmol/L are already
reached after one catalytic cycle due to the very high en-
zyme and substrate concentrations (Table 3). In initial
velocity solution studies, the enzyme concentration is
kept in the low micromolar range. Even under a saturat-
ing substrate (vmax) condition, only micromolar concen-
trations of product can be produced per turnover. With
a turnover rate of 0.8 s−1 of BlaC, it may take hours to
reach millimolar concentrations of product. In BlaC
crystals and with stoichiometric CEF concentrations (of
16 mmol/L for the shard crystal form, and 30 mmol/L
for the needles), however, these concentrations are
already reached after one turnover. Consequently, prod-
uct inhibition is not only plausible but likely, as previous
studies have shown that lactamases do show product in-
hibition by similar lactams with inhibitory constants in
the millimolar range [52]. In this scenario, after an initial
burst during the first second, the nucleophilic attack on
the lactam ring by Ser-70 represented by rate coefficient
k2 likely becomes the rate-limiting process (the E-CFO*
formation slows down), and the ES complex accumu-
lates later, as observed in our X-ray data.
Our results depend decisively on the ability of CEF to
penetrate the crystals. Although pore sizes for shard and
needle crystal forms largely differ (see above), CEF sub-
strate swiftly arrives at BlaC molecules in the crystals.
This is primarily due to the large substrate concentra-
tions that facilitate diffusion (see Methods and Table 3).
The osmotic pressure π of the outside CEF into the
crystals can be estimated as π =MRT, where M is the
molarity of the outside CEF concentration, R is the gas
constant, and T is the temperature in kelvins. This pres-
sure can be as high as 0.5 MPa (5 bar) with 300 mmol/L
CEF, which promotes rapid and uniform diffusion, even
in crystals with tight cavities such as those in our
needles (Table 3c). Diffusion may also be further en-
abled, and facilitated, by protein dynamics [53] at ambi-
ent temperatures. Although the reaction kinetics in
crystals might be different compared to that in solution
[54], structures of intermediate states that are occupied
along the catalytic pathway are highly relevant as long as
the enzyme is active in the crystal. With more conven-
tional X-ray sources, radiation damage might impede the
collection of even a single diffraction pattern [55] from
these microcrystals. The ultrashort, brilliant hard X-ray
pulses available at XFELs circumvent these difficulties.
With high X-ray pulse-repetition rates expected at
LCLS-II [56] and the European XFEL [57], a large num-
ber of finely spaced time delays may be collected rapidly
to allow for a comprehensive description of the reaction
in terms of structure and kinetics. Then the extraction
of a more accurate kinetic mechanism and the analytical
separation of mixtures into pure constituents become
possible [4, 58].
Conclusions
As we demonstrate here, the structural characterization
of enzyme-catalyzed reactions on the millisecond time
scale is possible by making use of very small crystals.
MISC can be employed to investigate a large number of
non-cyclic (single-pass) reactions in proteins and en-
zymes, some of which are of immense biological signifi-
cance and might be important targets for
structure-based drug design. MISC may become a major
tool to address fundamental questions on biomolecular
reactions at existing and new pulsed X-ray sources.
Methods
General overview
Using a continuous-flow mixing apparatus (Add-
itional file 1: Figure S1), we injected active microcrystals
of BlaC simultaneously with the β-lactam substrate cef-
triaxone (CEF) into a liquid jet for delivery to the beam
as a stream of randomly oriented hydrated nanocrystals
undergoing catalysis. The catalytic reaction is initiated
by solution mixing at the junction of two capillaries [38]
and the nanocrystals intersected by the X-ray pulse at
specific time points during the reaction. The use of
nanocrystals is essential for observation at short times
and for effective and uniform reaction initiation [28].
The 120-Hz repetition rate of LCLS allowed for the
rapid collection of diffraction snapshots at a number of
delay times (time points) after reaction initiation. Accur-
ate reflection intensities were extracted from the snap-
shots at each time point by indexing and Monte
Carlo-type integration [59, 60]. The data were phased
using the structural model for BlaC reported by Kupitz
et al. [30]. This model is based on the BlaC Protein Data
Bank (PDB) entry 2GDN [48]. The sequence convention
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reported in PDB entry 2GDN has also been used by
others [19], and we use it here throughout for homogen-
eity. Accordingly, we obtained, as a function of time, in-
formation on distinct chemical intermediates of
β-lactam substrates within the active site of BlaC. The
BlaC enzyme requires limited conformational changes to
execute catalysis, allowing us to observe the full enzym-
atic reaction within a crystal.
Crystal forms
Cloning, overexpression, and purification of M. tubercu-
losis BlaC was performed as described previously [30].
BlaC was crystallized in the shard crystal form as de-
scribed earlier [30]. The slurry was stirred overnight at
30 °C to avoid the growth of larger crystals that other-
wise need to be crushed to be suitable for MISC experi-
ments. Crystals grown this way were of dimensions 10 ×
10 × 3 μm3. An additional crystal form was obtained
from a different crystallization condition using the free
interface diffusion (FID) method [61]. In a 1.5-mL
Eppendorf tube, 250 μL of a precipitant solution (35%
PEG 1000, sodium acetate pH 5.0), was slowly added
dropwise through 250 μL of a protein solution at 10 mg/
mL. Needle-shaped crystals of dimensions 5 × 2 × 2 μm3
grew at room temperature in about 48 h. The microcrys-
talline sample was highly monodisperse as demonstrated
by dynamic light scattering (Additional file 1: Figure
S12). The suspension showed an intense second order,
non-linear imaging of chiral crystals (SONICC) signal
demonstrating the crystallinity of the sample. X-ray
powder diffraction was used as a quality test to verify
the existence of diffracting crystals. A very high-density
pellet of microcrystals was transferred to a transparent
plastic capillary (MiTiGen, Ithaca, NY, USA). A small
amount of precipitant solution was kept to prevent the
crystals from drying out. The capillary was mounted
onto a regular goniometer base, and data were collected
for 3 min on a Rigaku Micro Focus 007 high-flux X-ray
generator. Intense powder rings were observed up to
7 Å. Weaker rings were also observed to extend up to
approximately 4 Å.
Injectors
The mixing injectors used in this experiment were based
on the design by Calvey et al. [36] shown in Add-
itional file 1: Figure S1. In these devices, a crystal sus-
pension and a buffer (either 1 mol/L sodium phosphate
or sodium acetate, pH 5) containing 200–300 mmol/L
CEF are flowing in coaxial capillaries. The flows are
combined and forced into a constriction, thinning the
crystal flow to a narrow jet and allowing rapid CEF dif-
fusion. By varying the length of the device, the sample
and buffer flow rates, or by placing an expanded region
after the constriction, we were able to probe time scales
ranging from 30 ms to 2000 ms. Two high-performance
liquid chromatography (HPLC) pumps (Shimadzu
LC-20 AD) drove the flow. Crystals (shards: 10 × 10 ×
3 μm3, needles: 5 × 2 × 2 μm3) were held in a custom
reservoir built by Coherent X-ray Imaging (CXI) staff,
while the buffer was held in a larger reservoir (KNAUER
VariLoop), allowing water flow through the HPLC pump
without diluting either sample or buffer. A pressure con-
troller (Proportion-Air GP1) was used to regulate helium
pressure in the device. For each condition, the solution
is considered mixed when the CEF concentration ex-
ceeds 40 mM, which is sufficiently high to cause rapid
binding. The reported mixing times are the time for the
concentration around the average crystal to reach this
threshold, with upper and lower bounds given for the
first and third quartiles. In these calculations, the crys-
tals are assumed to be much smaller than the focused
jet, and fluctuations in flow rate are neglected. The mix-
ing times for each time point are reported in Table 1.
The delay time is defined as the time that the reaction is
allowed to proceed after mixing. During this time, the
crystals traverse the device before being probed by the
X-ray beam. Uncertainty in the delay time results from
errors in the sample and buffer flow rates (which come
from the factory specifications for the Shimadzu
LC-20 AD HPLC pumps that we used to drive the flows)
and from small variations in the diameters and lengths
of the capillaries used to make the mixing injectors.
Mixing injectors were designed so that the delay time
slightly exceeded the nominal time point to allow for
additional time for the ceftriaxone to diffuse into the
crystals. Table 1 lists the delay times and flow parame-
ters for different time points.
Data collection, data analysis, and structure
determination
Serial femtosecond crystallography (SFX) experiments
were performed at the CXI instrument [62]. Microcrys-
tals (10 × 10 × 3 μm3 shard-shaped crystals or 5 × 2 ×
2 μm3 needles) were mixed with the antibiotic ceftriax-
one (200–300 mmol/L) before injection into a vacuum
using a mixing jet injector (described above) that
allowed millisecond time resolution. Diffraction patterns
were recorded on a Cornell-Stanford Linear Accelerator
Center (SLAC) pixel array detector (CSPAD) [63] oper-
ating at 120 Hz to match the X-ray pulse frequency.
Data for shards and needles were analyzed in an identi-
cal fashion. Cheetah [64] was used to filter out diffrac-
tion patterns containing Bragg reflections. These
patterns were indexed and integrated using the CrystFEL
(version 0.6.2) program suite [60, 65]. Partial intensities
were scaled and merged using linear and Debye-Waller
factor scale factors. Data statistics are listed in Table 2.
The BlaC structures were solved for the needles and
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shards using molecular replacement by Phaser [66]. For
the shards, the structure determined by Kupitz et al. [30]
with four subunits (A–D) in the asymmetric unit was
used as the initial model. For the monomeric structure
in the needles, subunit D from this structure was ex-
tracted and used as a search model. Reference structures
Sref,n and Sref,s were determined for the needles and
shards, respectively, using the respective “unmixed” data
for both crystal forms. To determine structural changes
after mixing, difference maps were determined. For the
shards, unit cell changes on the order of 2 Å and larger
were observed after mixing. This prevents the calcula-
tion of isomorphous difference maps. With the needles,
however, unit cell changes were not observed (Table 2),
and isomorphous difference maps can be calculated. Ac-
cordingly, two different strategies were followed to
analyze the two types of data.
1. Structures for the shard crystal form. Since
isomorphous difference maps could not be
calculated, structural interpretation has been based
on omit difference maps. The reference model was
refined using simulated annealing (SA) in PHENIX
against the observed jFobst j. For this refinement,
water and phosphate molecules residing in the
active sites of all subunits were removed. In
addition Ser-70 was replaced by a glycine (Gly-70)
in subunits B and D. The structure was heated to
5000 K (default) and slowly cooled to 300 K. As a
result, a model of the apo-protein without any li-
gands in the active site was obtained. After the re-
finement, mFo-DFc omit difference maps Δρomitt
were calculated for each time point t, where the Fo
correspond to the jFobst j and the Fc are determined
from the refined (partial) model, m is the figure of
merit, and D is a coordinate error-dependent
weighting term [67, 68]. The resulting omit map is
essentially free of phase bias towards the ligand-free
“unmixed” structure.
Strong electron density appeared in subunits B and D
that was reminiscent of CEF molecules. In subunits A
and C, the electron density of only the phosphate and
the water molecules re-appeared, a result that was also
previously reported [30]. Hence, the structures of the
catalytic clefts in these subunits A and C were restored
back to the reference. The Δρomitt in the catalytic clefts of
subunits B and D was exceptionally strong at all time
delays (Fig. 3, Additional file 1: Figures S2–S4, S6). Ap-
propriate CEF species (Fig. 1) were placed in the positive
Δρomitt and initially real-space refined in Coot using ad-
equate crystallographic information files (CIFs), which
define the geometry and provide restraints. CIFs were
generated for the full-length ceftriaxone (CEF) as well as
an open form with the leaving group split off (E-CFO*)
as previously described [30]; compare also Fig. 1. One
oxygen of the open lactam carboxyl in E-CFO* was re-
moved, and the carboxyl carbon was connected to the
Ser70-Og with a weak distance restraint of 1.6 Å. At all
time points, either CEF, E-CFO* (bound to Ser-70), or a
mixture of both was observed. Their structures were
first refined in real space in Coot.
Mixtures of full-length, non-covalently bound CEF
configurations and Ser-70 bound, open forms (CFO)
were refined together in PHENIX. Note that E-CFO*
was replaced at 500 ms in subunit B with a species dis-
playing an alcohol (Figs. 1d, 3g and Additional file 1:
Figure S6b) instead of the double bond Δ, the structure
of which was refined as described. Further refinement
including occupancy refinement of the two species was
performed with PHENIX [69] against the jFobst j. Since a
large volume of electron density is shared by CEF and
the shorter E-CFO*, occupancy refinement is not reli-
able. Numbers obtained reflect the fact that the two
molecules are present. Essentially complete ligand occu-
pancy is reached at all time delays. Therefore, a potential
presence of an unmixed BlaC species was not taken into
account during the refinement. An additional CEF mol-
ecule, which can be identified near, but not bound to,
the active site (CEFstack) has been added to the last phase
of the refinement. The leaving group (the large
dioxo-triazine ring) is π-π stacking with the small
amino-thiazol ring of the CEF species in the active site,
resulting in an antiparallel alignment. Distances between
the rings are on the order of 3.5 Å. However, as men-
tioned later, the main interactions are with Tyr-127
Table 1 Mixing parameters for each time point. The buffer contained 200–300 mmol/L CEF in either 1.0 mol/L sodium phosphate
(shard crystal form), pH 5, or in 100 mmol/L sodium acetate, pH 5 (needle crystal form). The superscript and subscript numbers in
the second column indicate that deviations to shorter times are different from those to longer times
Nominal time point (ms) Mixing time (ms) Delay time (ms) Sample flow (μL/min) Buffer flow (μL/min) Constriction diameter (μm)
30 5þ6−3 42 ± 2 4.0 ± 0.5 66.0 ± 0.6 75 ± 1
100 10þ13−8 114 ± 4 10.0 ± 0.5 70.0 ± 0.7 75 ± 1
500 7þ10−5 510 ± 20 8.0 ± 0.5 32.0 ± 0.5 50 ± 1
2000 15þ20−11 2300 ± 50 10.0 ± 0.5 45.0 ± 0.5 75 ± 1
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Table 2 Data collection and refinement statistics
Reference 30 ms 100 ms 500 ms 2 s
(a) Shard-shaped crystals
Hits 98,895 35,065 88,413 158,620 39,140
Indexed images 73,170 24,397 79,328 134,583 32,201
Resolution (Å) 2.45 2.75 2.15 2.20 2.30
Space group P21 P21 P21 P21 P21
Unit cell (Å,o)











Volume (Å3) 804,442 807,597 817,098 809,346 789,415
BlaC/unit cell 8 8 8 8 8
Completeness 100(100) 100(100) 100(100) 100(100) 100(100)
Multiplicity 1221 (103.3) 526 (142.0) 895 (58.8) 1363 (81.3) 330 (59.0)
SNR 8.9(2.4) 6.4(0.9) 7.1(1.0) 8.3(0.9) 5.4(1.1)
Rsplit (%) 9.8(209.4) 14.2(121.1) 11.18(111.0) 9.7(126.3) 11.9(104.1)
CC-half (%) 99.4(41.1) 98.6(34.5) 99.4(37.5) 99.6(31.0) 96.8(35.4)
Refinement
Rcryst/Rfree (%) 19.2/24.4 19.3/25.0 20.9/23.9 21.9/25.0 23.5/26.6
*BCEF/E-CFO*a 0/0 91 (23b) 57/32 40/36c 58/25
*DCEF/E-CFO*a 0/0 89 (24b) 54/40 38/44 51/31
Stacking no yes yes yes yes
H2O 315 143 499 431 399
Average B value (Å2) 48.2 51.7 42.3 37.3 36.2
Protein amino acid residues in asym. unit 265 × 4 265 × 4 265 × 4 265 × 4 265 × 4
Ligands 0 2 + 2 (stacking) 2 + 2 (stacking) 2 + 2 (stacking) 2 + 2 (stacking)
RMSD bond lengths (Å) 0.008 0.010 0.008 0.008 0.008
RMSD bond angles (degrees) 1.10 1.72 1.66 1.67 1.74
PO4 4 2 2 2 2
(b) Needle-shaped crystals
Hits 171,314 64,507 115,223 141,935 36,606
Indexed images 111,466 34,590 87,580 87,058 23,278
Resolution (Å) 1.8 1.9 1.8 1.9 2.05
Space group P21 P21 P21 P21 P21
Unit cell (Å,o)











Volume (Å3) 110,375 110,096 110,323 110,908 110,908
Completeness (%) 100(100) 100(100) 100(100) 100(100) 100(100)
Multiplicity 985 (54.5) 330 (26.8) 831 (89.0) 806 (36.5) 238 (27.3)
Signal-to-noise ratio 9.6(1.2) 5.8(0.8) 9.6(1.6) 8.6(0.9) 5.1(1.1)
Rsplit (%) 6.6(97.0) 12.2(136.3) 6.6(72.5) 8.8(129.1) 14.0(105.9)
CC* (%) 99.9(75.0) 99.9(76.1) 99.9(84.3) 99.9(68.1) 99.8(74.8)
CC-half (%) 99.7(39.1) 99.4(40.4) 99.7(55.1) 99.7(30.2) 99.13(38.8)
Refinement
Rcryst/Rfree (%) 21.5/24.5 20.7/26.2 23.0/26.7 21.7/26.4 20.0/25.0
Nd na 9 9 6 5
CEF/E-CFO*a 0/0 59/0 51/35 43/53 71/0
Stacking no no no no no
H2O 167 203 154 104 175
Average B value (Å2) 34.7 16.9 10.5 15.7 18.3
Protein amino acid residues in asym. unit 265 265 265 265 265
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(between Tyr-127Oη and OI of the CEF
stack dihydrothia-
zine carboxyl) and Arg-126 (between Arg-126Nε and OI
of CEFstack-OI) of the adjacent (non-reactive) dimer sub-
unit (see Fig. 2b, c and Additional file 1: Figure S9).
CEFstack is pre-oriented this way very close to the active
site. In order to access the active site, CEFstack only has
to flip in, which may be initiated when the CFO species
leaves the active site. B-factors of the various CEF spe-
cies in the shard crystal form are shown in Additional
file 1: Table S1.
2. Structures for the needle crystal form. Difference
structure factor amplitudes ΔFisot were calculated
for each time point t by subtracting the observed
reference structure factor amplitudes jFobsref jcollected
with no CEF present from the time-dependent
structure factor amplitudes jFobst j. From the ΔFisot
and the phases derived from Sref,n, isomorphous dif-
ference maps were calculated. In order to model
the BlaC structure including a (potentially modified)
CEF ligand, conventional electron density maps ρextt
were calculated where the ligand occupancy was ex-
trapolated to 1.0. Extrapolated structure factors Fextt
were calculated by adding the ΔFisot N times (see
Table 2) to the calculated structure factors derived
from Sref,n. The extrapolated electron density ρextt
was derived from the Fextt . The structures of appro-
priate CEF derivatives (see above and Fig. 1) were
inserted using Coot [47]. At all time points, either
CEF, E-CFO* (bound to Ser-70), or a mixture of
both was observed (Fig. 3c, f, i, l). Their structures
were first refined in real space against the ρextt in
Coot. Further occupancy refinement was performed
as described above (1).
Enzyme kinetics
The Michaelis constant Km is on the order of 500 μmol/
L for BlaC with CEF, and kcat in solution is 0.8 s
−1 [40].
The koff rate coefficient of dissociation of substrate from
the active site as well as the diffusion coefficient of CEF in
the crystals are unknown. Accordingly, we need to assume
values that yield plausible results. When the koff rate coef-
ficient is assumed to be equal to the kcat rate coefficient in
solution, the kon rate coefficient for the binding of CEF is
kon ¼ 2xkcatKm ¼ 2x0:8500 x 10−6 L mol
−1s−1 ¼ 3200 L mol−1s−1 . As-
suming a diffusion coefficient of 2.3 × 10−6 cm2/s for CEF
in water [70], characteristic diffusion times τD into the
centers of the 10 × 10 × 3 μm3 shards and the 5 × 2 ×
2 μm3 needles would be a few milliseconds (Table 3c)
[28]. It should be mentioned here that diffusion times in
crystals may be very different from, and much slower
than, those in solution. At the characteristic diffusion
time, ð1− 1eÞ or 63% of the outside CEF concentration is
reached in the crystal center. Crystal suspensions are typ-
ically mixed 1:4 with large concentrations of CEF (be-
tween 200 mmol/L and 300 mmol/L). Mixing ratios can
be up to 1:17 for the fastest mixing times (Table 1). As a
result, the CEF solution is only slightly diluted after mix-
ing. The CEF concentration is much higher than the con-
centration of BlaC molecules in the crystals (16 mmol/L
in the shard crystal form, 30 mmol/L in the needles). The
stoichiometric concentration of CEF is reached at a time t,
much faster than τD. This time t can be estimated as
t = τD ∙ f where f = − lnð1− soutÞ , s is the concentration of
BlaC in the crystals, and out is the outside CEF concentra-
tion (Table 3c). f is ~ 0.1 for the shards and ~ 0.2 for the
needles (see Table 3c). The experiment becomes robust to-
wards variations in diffusion times caused by crystal size,
crystal morphology, and crystal packing. Pore sizes in the
shards (up to 90 Å) are up to four times larger than those
in the needles (see discussion above, and also Add-
itional file 1: Figure S11), which could severely impede dif-
fusion, especially of a molecule as large as CEF (554.6 g/
mol). As shown in Table 3c, diffusion times may be slower
by two orders of magnitude compared to those in solu-
tion, and still the substrate would diffuse sufficiently fast
to reach stoichiometric concentrations.
The time-dependent concentrations of species
along the enzymatic pathway were simulated by
Table 2 Data collection and refinement statistics (Continued)
Reference 30 ms 100 ms 500 ms 2 s
Ligands 0 1 1 1 1
RMSD bond lengths (Å) 0.008 0.007 0.007 0.003 0.008
RMSD bond angles (degrees) 1.06 1.57 1.74 1.49 1.57
*Bfor subunit B
*Dfor subunit D
aoccupancy of full-length, intact CEF to covalently bound, open E-CFO*, which has lost R. Numbers are rough estimates and should represent only trends (the
error is on the order of 25%, see note b)
bomit maps show only CEF in the active site. If E-CFO*‘s occupancy is refined at the same time, values around 24% are obtained. We consider this the error of our
occupancy refinement
cAddition of OH instead of the double bond Δ
dIf N does not extrapolate to 100% occupancy, a fraction of reference structure is present. This is ignored in the refinement
na not applicable
RMSD root mean square deviation
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numerically integrating the coupled differential equa-
tions of the simple kinetic mechanism shown in
Scheme 1 using the above rate coefficients which re-
produce the known Km. Note that formation of the
covalent E-CFO* complex (acyl intermediate) is irre-
versible due to the cleavage of the leaving group R
from CEF. Table 3a lists the parameters that enter
the calculation.
The substrate concentration S in the crystal is deter-
mined by the outside substrate concentration S0
(50 mmol/L in the simulation) and the characteristic diffu-
sion time τD. S is fed to the free enzyme E and bound to
the enzyme with k1. The total enzyme concentration was
set to 25 mmol/L. Results are shown in Fig. 4 and Table 3b
for τD = 15 ms (solid lines) and for τD = 1.5 ms (dashed
lines). Sufficient accumulation (occupancy) of the enzyme
substrate complex (ES, green) is achieved after 30 ms even
with the longer diffusion time (Fig. 4), which agrees with
our observations by MISC (Fig. 3a, b, c). Initially, k3 was
assumed to account for the rate-limiting process and set
to kcat = 0.8 s
− 1. As the low k3/Km ratio found in the litera-
ture [40] (~ 1.5 × 103 L mol−1 s−1) suggests, CEF binds
slowly to the enzyme. In Fig. 4, we show results for 1.5-ms
as well as 15-ms diffusion times. As the kinetics are very
similar, the MISC experiment is robust against crystal size
heterogeneities as well as against mixing time jitter
(Table 1). The ES complex accumulates slightly faster with
Table 3 Results from the simulations and estimates of diffusion times. (a) Parameters used in the simulation: apparent diffusion time
τD based on crystal size, initial enzyme concentration E0, outside substrate concentration S0, rate coefficients k1 … k3, and product
inhibition Ip (Scheme 1). (b) Occupancy of the various enzyme species as obtained by the simulation. They can be compared to
occupancy values listed in Table 2. E free enzyme, ES non-covalently bound ceftriaxone in the active site, with leaving group
present, E-CFO* enzyme intermediate with CFO bound covalently, P free product (CFO). (c) Diffusion times τD, and times t to reach
stoichiometric concentration in the shard and needle crystals. As an example, estimates for the 1:4 (crystal:CEF) mixing ratio are
listed. Time variations between 200 mmol/L and 300 mmol/L CEF are negligible. Times are lower limits, since they are estimated
from diffusion in water. Even if they are allowed to vary by orders of magnitude, sufficient occupancy would be achieved after
30 ms. They also imply that the time resolution may be given by the mixing times (Table 1) in some crystal forms, and not by the
diffusion times, since the former are longer than the latter
(a)
τD (ms) E0 (mmol/L) S0 (mmol/L) k1 (L mmol




15/1.5 25 200 3.2 0.01 7 0.8 6
(b)
0 ms 30 ms* 100 ms 500 ms 2 s
E (%) 100 10/2 2 1 1
ES (%) 0 84 58 19 59
E-CFO* (%) 0 6/14 40 80 40
P ([mmol/L) 0 0.05 0.5 5.8 23.4
(c)
Shard-shaped crystals Needle-shaped crystals
BlaC concentration in crystal 16 mmol/L 30 mmol/L
Average size([μm3) 10 × 10 × 3 5 × 2 × 2
τD 3.5 ms 0.8 ms
Mixing ratio crystal:CEF 1:4 1:4
CEF = 200 mmol/L
CEF after mixing 160 mmol/L 160 mmol/L
Time to reach stoichiometric conc. 0.36 ms 0.17 ms
CEF = 300 mmol/L
CEF after mixing 240 mmol/L 240 mmol/L
Time to reach stoichiometric conc. 0.24 ms 0.10 ms
*For 15-ms and 1.5-ms diffusion times, respectively
Scheme 1
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the fast diffusion time, but the kinetics are essentially the
same for both simulated diffusion times. The acyl inter-
mediate (E-CFO*, blue) forms essentially on the same time
scale (500 ms) for both crystal forms (Fig. 3 g, h, i). In our
MISC X-ray data we do not see clear evidence of a prod-
uct complex (EP) where the CFO has been hydrolyzed
(detached) from Ser-70 and is non-covalently bound to
the enzyme. It appears as if this product state is depopu-
lated faster than it is populated, and it therefore does not
accumulate sufficiently to be detected. Importantly, the ES
complex reappears in our MISC data at 2 s (Fig. 3j, k, l).
That means the E-CFO* cannot be the rate-limiting species
(with the hydrolysis of the covalent bond the rate-limiting
step); otherwise, E-CFO* would be the dominant species in
the steady state. However, if ES were initially rate-limiting
(and the nucleophilic attack of Ser-70 the rate-limiting
step), E-CFO* would not accumulate sufficiently to be de-
tected so clearly at 500 ms. To solve this dilemma, we as-
sume that rate coefficient k2 (the Ser-70 nucleophilic
attack) decreases with product concentration. Unlike in so-
lution, in the crystal enzyme and substrate concentrations
are so high that already after one turnover more than
10 mmol/L of substrate is converted to product. Accord-
ingly, on time scales > 1 s, product inhibition was assumed
by lowering k2: k2 ¼ k 02ð1−e−Pn=IpÞ, where Pn is the concen-
tration of the released product P divided by an characteristic
inhibitory concentration Ip in mmol/L (Table 3a). BlaC in-
hibition by penicilloic acids was also reported previously
[52]. This detail of the BlaC reaction awaits further investi-
gations which are outside the scope of this paper. By no
means do we suggest that this mechanism is unique. There
are only four time points (plus the unmixed, free enzyme
species). The rate coefficients in the mechanism may vary
widely and still reproduce the observations. Within a large
number of plausible mechanisms, our mechanism is the
simplest that explains our experimental observations at lim-
ited time points. If a more complex mechanism is to be jus-
tified, the collection of additional, more finely spaced time
points is necessary.
Additional file
Additional file 1: Figure S1. Schematics of the short-time-point mixing
injector. Figure S2. Selected views of the CEF binding site in the BlaC
shard crystals including simulated annealing omit maps. Figure S3. Structural
details, and simulated annealing omit maps, shard crystal form, subunit B
(stereo representation, from 30 ms to 2 s). Figure S4. Structural details and
simulated annealing omit maps, shard crystal form, subunit D (stereo represen-
tation, from 30 ms to 2 s). Figure S5. Structural details, and simulated annealing
omit maps, needle crystal form (stereo representation, from 30 ms to 2 s).
Figure S6. Backside view of the catalytic cleft of BlaC in the shard crystal form,
structural details and simulated annealing omit maps (stereo representation,
selected time points). Figure S7. 2mFo-DFc electron density in the catalytic
clefts of BlaC in the shard crystal form (stereo representation, from 30 ms to
2 s). Figure S8. 2mFo-DFc electron density and structural details in the
catalytic clefts of BlaC in the needle crystal form (stereo representation from
30 ms to 2 s). Figure S9. Details in the catalytic cleft of subunit B in the
shard crystal form at 500 ms including the stacked CEF, 2FoFc maps, and
simulated annealing omit maps (stereo representation). Figure S10. The
catalytic cleft of BlaC, further details, including a difference map between
the 500 ms and 100 ms time points. Figure S11. Crystal packing in shards
and needles. Figure S12. Dynamic light scattering results. Table S1. B-
factors for CEF species observed in the shard crystals at different time delays.
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